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ABSTRACT
Background: Many studies have examined the relation-
ship between long-term radiographic damage and
physical function. However, it is not known if short-term
radiographic progression is also associated with physical
function.
Aim: To investigate the longitudinal relationship between
physical function and both the level of radiographic
damage and the radiographic progression rate in patients
with early or advanced active rheumatoid arthritis.
Methods: The database for the 2-year Trial of Etanercept
and Methotrexate with Radiographic Patient Outcomes
(TEMPO) was used for this study. Physical function was
measured by the Health Assessment Questionnaire (HAQ)
score at baseline, 6 months and 1 and 2 years.
Radiographs of the hands and feet, taken at the same
time points, were scored by the van der Heijde-modified
Total Sharp Score (TSS). The HAQ score was modelled
using generalised mixed linear modelling by TSS or
progression in TSS (interval 0–1 year and 1–2 years)
adjusted for age, sex, treatment and disease activity.
Results: After adjustment for age, sex and disease
activity, both TSS and the change in TSS (progression
rate) were significant determinants of the HAQ score.
When radiographic progression was divided into four
categories (negative, zero, minor and greater progres-
sion), results showed that HAQ scores tended to be
higher with a higher rate of progression. Patients with
negative progression scores had lower HAQ scores than
patients with positive progression scores.
Conclusions: Patients with greater radiographic damage,
and those with recent radiographic progression, have a
higher degree of disability.
Rheumatoid arthritis (RA) affects almost 1% of the
adult population.
1 Affected subjects experience
considerable morbidity, including a rapid loss of
function,
23joint destruction, permanent deformity
and reduced life expectancy.
45Based on published
guidelines,
67 treatment of RA should focus on
preserving function, preventing or controlling joint
damage and achieving remission of disease activity.
Progressive radiographic damage and deteriora-
tion in physical function occur in patients with RA
who do not receive timely effective treatment.
Several long-term prospective studies have looked
at the relationship between radiographic damage
and physical function in patients with RA.
8–10 A
prospective 6-year follow-up study by Kuper et al
10
showed that large joint damage occurs early in the
disease, with at least 20% of patients having
damage in at least one joint within 1 year of
disease onset and 50% of patients having some
damage within 6 years of disease onset.
Radiographic changes were significantly related to
damage in the hands and feet, the physical
disability index and cumulative disease activity.
10
In a review of the links between joint damage and
disability in patients with RA, Scott et al reported
that joint damage progresses continuously over the
first 20 years of RA and that this damage accounts
for 25% of the disability seen in patients.
9
Radiographic damage is thus clearly a major
determinant of long-term physical function in
patients with established RA.
Although studies have shown that a relationship
between physical function and radiographic
damage exists, they have mostly examined this
association looking at radiographic damage over
the long term. It is not known whether progression
of radiographic damage over short periods is
associated with immediate impairment in physical
function. This question is particularly relevant
today because of the availability of powerful
treatments that can prevent radiographic progres-
sion if started early enough. For example, in clinical
trials, etanercept, either alone or in combination
with methotrexate, has been shown to reduce
radiographic progression in patients with recent
and long-term RA.
11–13
Our study used data from the Trial of Etanercept
and Methotrexate with Radiographic Patient
Outcomes (TEMPO),
11 14 to investigate the long-
itudinal relationship between physical function and
both level of radiographic damage and radiographic
progression over a 2-year period, in a cohort of
patients with early or advanced active RA.
METHODS
TEMPO was a multicentre, double-blind study
that compared the effect of etanercept plus
methotrexate versus etanercept alone versus meth-
otrexate alone in 686 patients with active RA of
6 months to 20 years’ duration.
11 14 Details of this
trial are published elsewhere.
11 14–16
All patients were randomly assigned to one of
three treatment groups: etanercept (25 mg
twice-weekly subcutaneous doses), methotrexate
(7.5–20 mg weekly oral doses) or combination
therapy with etanercept and methotrexate.
Physical function was measured by the Health
Assessment Questionnaire (HAQ) at baseline and
at protocol-specified intervals throughout the
study; scores at baseline and 1 and 2 years were
used in the analysis. The HAQ is scored on a scale
of 0–3, with higher scores indicating increased
disability.
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baseline, 6 months, 1 year and 2 years. Digitised images were
scored by two readers, using the van der Heijde-modified Sharp
method.
17 Radiographic progression was determined for each
interval by subtracting status scores of two time points.
Radiographic progression was divided into four categories
(negative, ,0; zero, 0–1; minor, 1–5; and greater progression,
.5) for comparisons with HAQ scores. The radiographic
population consisted of patients who had an acceptable baseline
and at least one acceptable post-baseline film.
Statistical analysis
To control for within-patient correlation, generalised mixed
linear modelling was used to model the dependent variable
HAQ score by the absolute Sharp score (damage score) or the
interval change in Sharp score, with age, sex, disease duration,
treatment, Disease Activity Score (DAS) and C-reactive protein
(CRP) levels as covariates. If interval change in Sharp score was
entered as an independent variable, the HAQ score at the end of
the interval was chosen as the dependent variable in the model
and the HAQ score at baseline was omitted. A random intercept
and a compound symmetry covariance structure seemed to best
fit the data. Results are expressed as estimated marginal means.
In separate analyses, the interaction of disease duration and
(change in) Sharp score with respect to HAQ score was tested.
RESULTS
Of the 686 randomly assigned patients, 622 (91%) had a baseline
and at least one follow-up film and were included in the
radiographic analysis. No statistically significant differences
were found among the three treatment groups in baseline
demographic and disease characteristics. Patients included in the
analysis were predominantly women (76.5%), with mean
disease duration of 6.35 years, mean HAQ score of 1.72 and
mean total Sharp score (TSS) of 33.0 at baseline.
In the linear mixed model, which was applied here in order to
aggregate data of baseline, year 1 and year 2 data under
simultaneous adjustment for within-patient correlation, the
TSS was significantly positively associated with the HAQ score
independently of the DAS (table 1). A number of additional
variables were independently associated with the HAQ score,
including age (positive correlation), sex (women had higher
HAQ scores) and the DAS (positive correlation).
The HAQ score is primarily determined by disease activity. In
the context of a clinical trial, it is expected that the disease
activity would show important variation that would easily
obscure a contributory and independent association with
radiographic damage or progression. We first investigated the
relationship between the DAS and the HAQ score. After
adjustment for age and sex, the relationship between DAS
and the HAQ score was almost linear (fig 1). This linear
relationship justifies why in every subsequent analysis to
determine the contribution of radiographic damage to explain-
ing physical function we have adjusted for the known relation-
ship between the DAS and the HAQ score.
To visualise the adjusted relationship between the HAQ score
and the Sharp score, Sharp scores were divided into six
categories of 10 Sharp units each and estimated marginal means
were calculated. Figure 2 shows estimated marginal means of
the fitted model (mean HAQ scores adjusted for age, sex, DAS,
treatment and time) for each category of 10 Sharp units and
clearly points to an increasing trend. A separate analysis, in
which the Sharp score was replaced by the change in Sharp
score, also indicated that the change in Sharp score (interval
progression; Sharp units per year) was significantly and
independently associated with the HAQ score (p=0.001;
table 2). This implies that patients who show joint damage
progression have worse physical function, independent of
disease activity and the type of treatment they use, although
the effects were small.
Figure 3 shows the effect of changes in radiographic damage
on physical function, with progression of radiographic damage
Table 1 Sharp score is positively associated with Health Assessment
Questionnaire (HAQ) score independently of Disease Activity Score




95% CI of the regression
coefficient
Lower bound Upper bound
Intercept 20.125 0.26 20.342 0.092
Sex (F) 20.243 ,0.001 20.333 20.152
Age (years) 0.0103 ,0.001 0.0073 0.0133
Disease duration (years) 0.0059 0.174 20.0026 0.0143
CRP (mg/dl) 0.0029 ,0.001 0.0014 0.0044
Treatment 0.0104 0.67 20.0369 0.0577
DAS 0.255 ,0.001 0.240 0.2688
Sharp score (Sharp units) 0.0019 ,0.001 0.0011 0.0027
*Dependent variable: HAQ.
CRP, C-reactive protein.
Figure 1 Marginal means for the Health Assessment Questionnaire
(HAQ) score, adjusted for age, sex, disease duration, treatment, Sharp
score and time as a function of disease activity score (DAS) in
categories of one unit (error bars reflect standard error).
Figure 2 Marginal means for the Health Assessment Questionnaire
(HAQ) scores adjusted for age, sex, disease duration, treatment, Disease
Activity Score (DAS), Sharp score and time as a function of increasing
Sharp scores (in categories of 10 units; error bars reflect standard error).
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progression). HAQ scores tended to increase with increasing
radiographic progression, although the differences were small
and probably not clinically meaningful. Figure 3 also suggests
that patients with negative progression scores have lower HAQ
scores than patients with positive progression scores, but this
effect was not statistically significant.
In an attempt to determine whether the documented
association between the Sharp score and the HAQ score, as
well as the association between the change in Sharp score and
HAQ score, was dependent on disease duration, we tested the
following interactions: Sharp score and disease duration and
change in Sharp score and disease duration, with disease
duration dichotomised at a cut-off level of 3 years, with respect
to explaining variation in HAQ score. Both interactions were
not statistically significant (results not shown)
DISCUSSION
This analysis provides further evidence for the longitudinal
relationship between radiographic damage and physical func-
tion. As shown, progression of radiographic damage over short
periods of time is associated with worse physical function,
which is independent of the effects of inflammatory disease
activity (DAS). In addition, patients who had negative radio-
graphic progression tended to have better physical function
than patients with zero or low positive progression scores. This
finding gains importance in the light of the low radiographic
progression rates that were found in the 2-year TEMPO trial.
14
Despite these low progression rates, this (sensitive) longitudinal
analysis suggests that any type of radiographic progression has
repercussions for physical functioning. It may be argued that
DAS and CRP inappropriately reflect disease activity and that
the proposed association between radiographic progression and
physical function would disappear if a variable that better
reflects inflammatory activity were used. This is, however,
highly unlikely. The contribution of radiographic progression to
the HAQ score was similarly high before and after adjustment
for DAS and CRP, so that both effects are truly separated (data
not shown).
In a 10-year longitudinal study,
18 we have previously observed
that radiographic damage and disease activity independently
contribute to changes in physical function in RA regardless of
disease duration. Others have reported the longitudinal relation-
ship between joint damage and physical function after
adjustment for disease activity.
19 In that particular study,
performed on an inception cohort of patients with RA followed
up for many years while receiving standard conventional
antirheumatic treatment, the main driver of physical function
was determined to be disease activity. But Welsing et al also
found a significant contribution of joint damage (measured by
van der Heijde’s modification of the Sharp score) to explain the
variation in physical function.
19
There are important differences between these previous
studies
18 19 and our current study: First, we analysed a trial
population using highly effective treatments. In our study,
radiographic progression was minimal, although the level of
baseline damage was, on average, substantial. Apart from that,
the active trial treatment resulted in very low levels of disease
activity in the majority of the trial population. Even with such a
low level of variation in the determinants of function (disease
activity and radiographic damage/progression) a relationship
between radiographic damage progression and the HAQ score
was suggested by this analysis. Second, in our study, we
investigated the contribution of radiographic progression itself,
rather than radiographic damage at any particular time point.
Our analysis suggests that both the level of damage, and the
progression rate, although very low, contributed to variation in
physical function. Third, our observations were made in a 2-
year follow-up study, whereas the previous studies
18 19 investi-
gated function over a period of 9–12 years, in which deteriora-
tion of physical function is likely to be far more substantial.
Taken together, however, the longitudinal studies provide
evidence that physical function in patients with RA is
determined not only by disease activity but also by radiographic
damage and the rate at which radiographic damage increases
over time. Fluctuations in the progression rate and in the disease
activity cause demonstrable effects on physical function within
very short time intervals. These data add to the ever-growing
evidence that it is important not only to suppress disease
activity but also to halt radiographic progression to maintain
physical function.
It is not a coincidence that studies using longitudinal data
analyses are consistent with the existence of a relationship
between radiographic damage and physical function. It has been
hypothesised that this relationship exists, but it has turned out
to be rather difficult to confirm it statistically in studies using
cross-sectional analytical approaches.
20 21 A longitudinal data
analysis provides far more statistical power because it uses all
available data of a prospectively followed cohort in an
aggregated manner, while adjusting for spurious intra-patient
correlation. Apart from that, longitudinal data analysis provides
insight into how changes in disease activity and radiographic
Table 2 Health Assessment Questionnaire (HAQ) score is positively
associated with radiographic progression rate independently of disease
activity (Disease Activity Score (DAS) and C-reactive protein (CRP)):




95% CI of the regression
coefficient
Lower bound Upper bound
Intercept 20.0142 0.922 20.3007 0.2723
Sex (F) 20.3118 ,0.001 20.4307 20.1928
Age (years) 0.0120 ,0.001 0.0080 0.0159
Disease duration (years) 0.0113 0.057 20.0015 0.0241
CRP (mg/dl) 0.0024 0.085 0.0003 0.0051
Treatment 0.0026 0.934 20.0997 0.0649
DAS 0.2313 ,0.001 0.1969 0.2658
Change in Sharp score
(Sharp units/year)
0.0088640 0.001 0.0035 0.0143
*Dependent variable: HAQ
Figure 3 Marginal means for the Health Assessment Questionnaire
(HAQ) score, adjusted for age, sex, disease duration, treatment,
disease activity score (DAS), Sharp score and time, as a function of
change in Sharp score (four categories of progression; error bars reflect
standard error).
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influence physical function.
Physical function is often considered to be a rather static
outcome. However, recent experience from randomised clinical
trials evaluating highly effective treatments has shown that
impairment of physical function in patients with RA is
reversible to some extent. In a recent analysis, Aletaha et al
reported that the irreversible part of the HAQ score was
between 0% and 33%, increasing with the duration of RA.
22 We
hypothesise that this irreversible impairment is caused by
structural damage, while the reversible impairment is primarily
inflammation. If true, early effective intervention to limit
structural damage may be helpful in decreasing irreversible
physical impairment.
Many studies support the use of early treatment of RA.
Landewe ´ et al showed that the best way to prevent radiographic
damage is to start treatment before such damage has occurred.
23
If this is not possible, aggressive treatment should be started
within 12–24 months after the diagnosis of RA to limit
radiographic progression over time.
23 Anderson et al showed
that the rate of radiological progression is set during the early
stages of RA and suggested resetting this progression rate
through pharmacological treatment as soon as possible after the
disease is recognised.
24 Other studies support the finding that
radiographic damage occurs early in the onset of RA and
progresses throughout the disease.
2 3 25–27 A recent meta-analysis
showed that starting treatment early has a long-term benefit on
inhibition of structural damage.
28 This analysis demonstrated
that the association between radiographic progression and
physical function was similarly important in relatively early
RA (disease duration (3 years) as compared with more
advanced RA (disease duration .3 years), which emphasises
the importance of minimising radiographic progression at all
stages of the disease.
Rheumatologists frequently question whether the small
differences in radiographic progression between trial arms are
clinically meaningful. This analysis supports the view that
subtle differences in radiographic progression have a measurable
impact on physical function, although most probably at a level
that is not truly clinically meaningful for the patient over a
relatively short period. The question, however, is how physical
function would be influenced if mild progression were allowed
for years and years, using the argument that small fluctuations
are not clinically meaningful.
CONCLUSIONS
This analysis suggests that in patients with RA, greater
radiographic damage and recent radiographic progression
correlate with a higher degree of disability, after adjustment
for age, sex, disease duration and disease activity.
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